Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Common Equity: 2021-2024

Historic Common Equity for Amylyx Pharmaceuticals (AMLX) over the last 4 years, with Dec 2024 value amounting to $164.8 million.

  • Amylyx Pharmaceuticals' Common Equity rose 69.21% to $332.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $332.0 million, marking a year-over-year increase of 69.21%. This contributed to the annual value of $164.8 million for FY2024, which is 61.99% down from last year.
  • Latest data reveals that Amylyx Pharmaceuticals reported Common Equity of $164.8 million as of FY2024, which was down 61.99% from $433.4 million recorded in FY2023.
  • Amylyx Pharmaceuticals' 5-year Common Equity high stood at $433.4 million for FY2023, and its period low was -$151.2 million during FY2021.
  • Over the past 3 years, Amylyx Pharmaceuticals' median Common Equity value was $340.6 million (recorded in 2022), while the average stood at $312.9 million.
  • Its Common Equity has fluctuated over the past 5 years, first soared by 325.32% in 2022, then tumbled by 61.99% in 2024.
  • Over the past 4 years, Amylyx Pharmaceuticals' Common Equity (Yearly) stood at -$151.2 million in 2021, then spiked by 325.32% to $340.6 million in 2022, then increased by 27.25% to $433.4 million in 2023, then plummeted by 61.99% to $164.8 million in 2024.